

Published in final edited form as:

*Cancer Cell*. 2011 August 16; 20(2): 173–186. doi:10.1016/j.ccr.2011.07.013.

## Identification of *PHLPP1* as a tumor suppressor reveals the role of feedback activation in *PTEN*-mutant prostate cancer progression

Muhan Chen<sup>1</sup>, Christopher P. Pratt<sup>1,8</sup>, Martha E. Zeeman<sup>1,8</sup>, Nikolaus Schultz<sup>2</sup>, Barry S. Taylor<sup>2</sup>, Audrey O'Neill<sup>3</sup>, Mireia Castillo-Martin<sup>4</sup>, Dawid G. Nowak<sup>1</sup>, Adam Naguib<sup>1</sup>, Danielle M. Grace<sup>1</sup>, Jernej Murn<sup>1</sup>, Nick Navin<sup>5</sup>, Gurinder S. Atwal<sup>1</sup>, Chris Sander<sup>2</sup>, William L. Gerald<sup>6,\*</sup>, Carlos Cordon-Cardo<sup>4</sup>, Alexandra C. Newton<sup>3</sup>, Brett S. Carver<sup>7</sup>, and Lloyd C. Trotman<sup>1,@</sup>

<sup>1</sup>Cold Spring Harbor Laboratory, One Bungtown Road, Cold Spring Harbor, New York 11724, USA.

<sup>2</sup>Computational Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

<sup>3</sup>Department of Pharmacology, University of California San Diego, La Jolla, California 92093, USA.

<sup>4</sup>Department of Pathology, Columbia University, New York 10032, New York, USA.

<sup>5</sup>Department of Genetics, Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX 77030, USA.

<sup>6</sup>Department of Pathology, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

<sup>7</sup>Department of Surgery, Division of Urology, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

### Summary

Hyper-activation of the PI 3-Kinase/AKT pathway is a driving force of many cancers. Here we identify the AKT-inactivating phosphatase PHLPP1 as a prostate tumor suppressor. We show that *Phlpp1*-loss causes neoplasia and, upon partial *Pten*-loss, carcinoma in mouse prostate. This genetic setting initially triggers a growth suppressive response via p53 and the *Phlpp2* ortholog, and reveals spontaneous *Trp53* inactivation as a condition for full-blown disease. Surprisingly, the co-deletion of *PTEN* and *PHLPP1* in patient samples is highly restricted to metastatic disease and

© 2011 Elsevier Inc. All rights reserved.

@Correspondence: Lloyd C. Trotman (trotman@cshl.edu), Phone: (516)-367-5054, Fax: (516)-367-8454.

<sup>8</sup>Equal contribution

\*Deceased

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Competing Interests Statement** The authors declare that they have no competing financial interests.

#### Accession numbers

Microarray data generated in this study have been deposited in the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>) with the accession number GSE30987.

tightly correlated to deletion of *TP53* and *PHLPP2*. These data establish a conceptual framework for progression of *PTEN*-mutant prostate cancer to life-threatening disease.

## INTRODUCTION

With an annual average of 200,000 cases in the United States (US) alone, cancer of the prostate (CaP) is the most commonly diagnosed malignancy in western men and the second most common cause of US male cancer deaths (ACS, 2007–2009). Due to effective CaP screening programs, an increasing number of men is diagnosed and treated for clinically localized CaP even if the majority will not progress to life-threatening disease. Therefore, identification of men who will suffer disease recurrence constitutes the great challenge for CaP therapy (Shariat et al., 2008).

Recent advances in whole genome analysis are affording us with a look at the bulk of alterations that occur in cancer tissue and in commonly used cancer cell lines. In prostate, several such whole genome efforts have identified and validated commonly observed events, such as *PTEN* deletions, *ERG* fusion genes and chromosome 8 aberrations (Lapointe et al., 2007; Saramaki and Visakorpi, 2007). Furthermore, comparative copy number analysis of metastatic CaP has demonstrated how this technology can be used to trace the process of disease dissemination (Liu et al., 2009). Most recently, the integration of gene copy number, gene mutation and transcriptome analysis has provided a comprehensive look at the nature of the changes that separate indolent from aggressive disease, since the extent of copy number alteration could be linked to a patient's risk of disease recurrence after prostatectomy (Taylor et al., 2010). Collectively, these studies demonstrate that advances in comprehensive cancer analysis could soon afford us with the catalog of changes associated with lethal disease progression in a patient – a prerequisite for the goal of effective patient-based target therapy (Schreiber et al., 2010). However, extraction of the relevant alterations that constitute a driving force for disease still poses a major challenge (Chin et al., 2011). Aberrant PI 3-Kinase pathway signaling is common in CaP and its specific targeting holds great therapeutic potential (Majumder and Sellers, 2005; Taylor et al., 2010; Wong et al., 2010). Therefore, it is paramount to understand which pathway players, together or alone, can be regarded as sentinels of pathway deregulation when they are found to be mutated.

Modeling the relevance of disease associated genes in Genetically Engineered Mice (GEMs) has proven to be the gold standard for establishing causality in cancer (Frese and Tuveson, 2007). Research using *Pten*-mutant GEM models of CaP has revealed that genetic context dictates disease outcome through both extent and cellular distribution of Akt activity (Carver et al., 2009b; Di Cristofano et al., 2001; Majumder et al., 2003; Trotman et al., 2006; Trotman et al., 2003). Thus, these studies highlighted the role of gene alteration events that cooperate to enhance AKT/PI 3-Kinase signaling in prostate cancer. *PTEN* prevents activation of AKT by dephosphorylating the membrane phospholipid PIP<sub>3</sub> (Maehama and Dixon, 1998). Thus, loss of *PTEN* results in increased AKT recruitment to the plasma membrane (PM), where it is activated by PDK-1 kinase through phosphorylation on the threonine-308 (Thr<sup>308</sup>) residue. The second Akt activating kinase consists of the mTOR complex 2 (mTORC2), which phosphorylates serine-473 (Ser<sup>473</sup>) on AKT (Sarbasov et al., 2005). *In vitro* results have led to the conclusion that dual activation of AKT is essential for activity, a notion that has been challenged by recent results obtained *in vivo* using genetic interference with the mTORC2 complex (as recently reviewed (Alessi et al., 2009)).

Recently, *PHLPP1* and *PHLPP2* have been identified through a search for genes that combine a phosphatase with a PH domain, reasoning that such a design would counteract PH domain containing kinases like AKT. Indeed the *PHLPP1/2* serine/threonine

phosphatases have been shown to directly inactivate AKT and PKC (Brognard et al., 2007; Gao et al., 2008; Gao et al., 2005). In addition to their roles in growth control, they have been implicated in memory formation and maintenance of circadian rhythms in mice (Masubuchi et al., 2010; Shimizu et al., 2010).

Recent genetic studies in mice have shown that neoplasia and cancer in *Pten*-deficient prostate depend on Akt activation on Ser<sup>473</sup> by mTorc2 (Guertin et al., 2009). Since PHLPP1/2 are the two known phosphatases to specifically revert this activation, we sought to determine the relevance of *PHLPP1* as a tumor suppressor by combining GEM modeling with patient whole genome analysis.

## RESULTS

### *Phlpp1* is a tumor suppressor in mouse prostate

By crossing *Pten*<sup>+/-</sup> with *Phlpp1*<sup>-/-</sup> mice we generated a cohort containing more than 400 mice of six genotypes (note that *Pten*<sup>-/-</sup> mice are embryonic lethal). As shown in Figure 1A, complete loss of *Phlpp1* in *Pten*<sup>+/-</sup> mice caused strong reduction of overall lifespan. Pathology analysis of these cohorts revealed acceleration of the polyclonal autoimmune disorder, which constitutes the major cause of death in our *Pten*<sup>+/-</sup> animals (Di Cristofano et al., 1999) (not shown). Loss of *Phlpp1* on its own also significantly reduced overall lifespan, presumably due to the observed lymphadenopathy (not shown). These observations prompted us to determine the tumor suppressor role of *Phlpp1* in greater detail. We focused on the role of *Phlpp1* in prostate tumorigenesis, a tissue that is very sensitive to the degree of Akt pathway activation (Trotman et al., 2003).

As shown in Figures 1B and 1C (bottom panel), prostates of *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> animals revealed regions of high grade prostatic intraepithelial neoplasia (HGPIN), which is characterized by an intraglandular proliferation of crowding cells with atypia, enlarged nuclei and prominent nucleoli, and invasive adenocarcinoma (characterized by the proliferation of atypical cells which break the basal membrane and invade through the prostatic stroma) at full penetrance with onset at 8 months (see also summary in Figure S1A). In contrast, prostates of *Pten*<sup>+/-</sup> mice only suffered hyperplasia (characterized by the proliferation of luminal with no cytological atypia) and HGPIN with onset after 8 months (Figure S1A), as previously published (Di Cristofano et al., 2001; Podsypanina et al., 1999; Trotman et al., 2003). While the *Pten*<sup>+/-</sup>; *Phlpp1*<sup>+/-</sup> mice did not develop foci of invasive adenocarcinoma (Figure 1B), they showed hyperplasia and low grade PIN, starting as early as 4 months and HGPIN at 8 and 12 months (see Figure S1A and also Figure 2C). Collectively, these data were consistent with a gene dose-to-effect relation of progression previously identified for *Pten* alone (Trotman et al., 2003). Importantly, we found that *Phlpp1*-loss on its own triggered HGPIN at full penetrance within 9 months of age (Figure 1C and Figure S1A) and one case of invasive adenocarcinoma at 12 months (Figure 1B, Figure S1A, 12 months). This was confirmed by immunohistochemistry (IHC) for the basal cell marker cytokeratin 5, which is lost in the invasive malignant glands (Figure S1B, left panels, red arrows). Furthermore by staining early neoplasia for p63, we found no expansion of basal cells (Figure S1B, right panels).

*Pten*-alteration in mouse prostate leads to increased proliferation, so we assessed Ki-67 staining over time. As shown and quantified in Figure 1D, the *Pten*<sup>+/-</sup> and *Phlpp1*<sup>-/-</sup> tissue showed similar rates of proliferation in the few earliest hyperplastic regions (4 months) and in the neoplasms at 8 months and 12 months. In contrast, we observed a sharp increase in proliferation upon combined loss but only after 4 months, thus quantitatively demonstrating that the two genes synergize in a time-dependent manner. Next, we quantified malignancy by measuring average lesion sizes of the 5 cohort arms at 3 time points. As shown (Figure

S1C), combined gene loss strongly cooperated to produce disproportionately larger lesions over time. Moreover, we found that changes in apoptotic rates could not account for tumorigenesis as they slightly increased (not decreased) in *Phlpp1*- and compound mutants, nor could we detect inflammatory responses as a cause of prostate malignancy (Figure S1D). Collectively, our results demonstrate that *Phlpp1* acts as a tumor suppressor in mouse prostate, and that its loss is synergistic with partial *Pten*-loss, but in a time-dependent manner.

### Phlpp1 blocks Akt activation at the epithelial plasma membrane

Since *Phlpp1* has been shown to directly dephosphorylate Ser<sup>473</sup> of Akt (Gao et al., 2005), we sought to determine the phosphorylation of Akt (pAkt) in prostates of our mice. As shown in Figure 2A, loss of *Phlpp1* affected pAkt activation on Ser<sup>473</sup>. We have been unable to detect significant above background phosphorylation on Thr<sup>308</sup> in *Phlpp1*<sup>-/-</sup> prostates. While these data are consistent with the published Ser<sup>473</sup> specificity of Phlpp1 we cannot exclude additional (especially indirect) activation of Akt on Thr<sup>308</sup> in *Phlpp1*<sup>-/-</sup> prostate (see below). In the context of *Pten*-heterozygosity, *Phlpp1*-loss also increased Ser<sup>473</sup> phosphorylation and consistently showed a marked effect on Thr<sup>308</sup> (see Figure 2A and Figures S2A, B for double heterozygous prostate and further quantification, respectively).

PHLPP1 has also been implicated in MAP-kinase and PKC signaling (Gao et al., 2008; Shimizu et al., 2003), yet in the prostates of compound mutant mice we did not find an increase in MAP-kinase pathway signaling (Figure 2B) and no consistent effects on PKC-beta levels (not shown) but confirmed Gsk3-beta, 4Ebp1 and S6 phosphorylation, while Foxo3a and Pras40 were not detectably affected (Figure S2C). Moreover, loss of *Phlpp1* had no general effect on *Pten*-levels (See Figure 2A, top panels). However, microscopic analysis revealed the presence of some glands with spontaneously reduced *Pten* protein and correlating pAkt Ser<sup>473</sup> activation in the *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> lesions (Figure S2D). In the absence of an equally effective IHC antibody for pAkt Thr<sup>308</sup> activation, we assume that this reduction in *Pten* levels is contributing to the observed activation of pAkt Thr<sup>308</sup> above background levels in the *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> tumors (Figure 2A, last lane).

We have previously shown that the cellular localization of activated Akt greatly varies in different CaP models: strong PM association is seen in the conditional *Pten*-null model (Trotman et al., 2003), while tumors in *Pten*<sup>+/-</sup>; *Pml*<sup>-/-</sup> animals show strong nuclear pAkt localization and activity (Trotman et al., 2006) causing female sterility *via* Foxo3a inhibition (Castrillon et al., 2003; Trotman et al., 2006). The membrane associated pAkt activation after complete *Pten*-loss correlates with senescence arrest *in vitro* and *in vivo* (Alimonti et al., 2010; Chen et al., 2005). Using immunohistochemistry time course analysis at 4, 8 and 12 months (Figure 2C), we found patchy above-background cytoplasmic pAkt Ser<sup>473</sup> localization in *Pten*<sup>+/-</sup> prostates. In *Phlpp1*<sup>-/-</sup> prostate, we observed a similar stain, also at all time points, confirming comparable overall Akt activation levels seen in Figure 2A. At 4 months, the compound mutant prostates revealed no major difference compared to the single mutant tissues. However, a striking shift of pAkt signal to the PM was observed in 8 month and 12 month compound mutant prostates. At these two time points, we found strong foci of Akt-activation, which over time increased both in size (Figure 2C, two right most columns, 8 months and 12 months) and number (not shown). Moreover, we found that these pAkt-foci typically correlated with patches of slightly reduced *Pten* protein (Figure S2D).

Together, our findings are consistent with a *Phlpp1*-dose dependent phenotype as the activation foci were more dominant in *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> than in double heterozygous mice. Therefore, the degree of Phlpp1 activity in the prostate epithelium controls pAkt concentrations at the PM after partial *Pten*-loss. Finally, we determined if this pAkt

localization was due to the cellular distribution of Phlpp1 itself. As shown (Figure S2E), the Phlpp1 protein has several domains that could direct it to the PM. Using a human PHLPP1 antibody, we confirmed strong membrane localization of PHLPP1 in human prostate epithelium (Figure 2D) and readily identified differential PHLPP1 expression levels on a human Tumor Tissue Microarray (Figure 2E). Thus, we conclude that Phlpp1 acts at the prostate epithelial membrane to antagonize Ser<sup>473</sup>-activation of Akt and that its loss, especially after Pten deregulation, can direct pAkt signaling to the plasma membrane.

### ***Phlpp1*-loss triggers p53 activation in *Pten*<sup>+/-</sup> prostate**

The above data revealed focal full-blown pathway activation that occurred only after a certain latency and in compound mutants, consistent with the delayed onset maximal proliferation observed in the double-mutant genotypes quantified in Figure 1D. Since *Pten*-loss triggers PM Akt activation and p53-mediated senescence (Alimonti et al., 2010; Chen et al., 2005; Kim et al., 2006) (as recently reviewed (Collado and Serrano, 2010)), we next determined if inactivation of *Phlpp1* in *Pten*<sup>+/-</sup> mice could affect p53. As shown in Figure 3A, *Phlpp1*<sup>-/-</sup> and also *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> prostates showed elevated p53 levels at 8 months. This increase was consistently observed in p53 protein while p53 transcript levels remained the same (Figure S3A). However, we failed to detect a corresponding increase in p21 transcription. On the contrary, we found lower p21 transcription in these same prostate samples (Figure 3B) suggesting spontaneous p53 loss-of-function.

To explore the state and activity of p53 during the neoplastic process in more detail, we studied prostates of WT and *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> mice at 4, and 6 months of age and found high p53 levels in the double mutants already at 4 months (see Figure 3C). Yet, the *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> prostate did show a p21 response at 4 months relative to WT prostate, which was absent from the 6 month time point, suggesting that p53 was transiently active. Next, we validated this p53 activation and inactivation scenario between 4 and 6 month samples by transcriptome analysis for p53 activation signatures in the same two compound mutant samples shown in Figure 3C (see Experimental Procedures). As shown in Figure S3B, we found p53 target gene upregulation (including p21) at 4 months. This however was absent from the 6 month old prostate sample, confirming lack of p53 activity at this time point, in spite of high protein levels in the same sample. We also noted elevated transcripts of the prostate senescence associated *SerpinE1/Pai-1* gene (Chen et al., 2005) at 6 months (see Figure S3B) and validated elevated *Pai-1* transcripts by qPCR (Figure S3C, 6 months). However, we found *Pai-1* strongly reduced in the 8 month old double mutant prostate (Figure S3C, 8 months), similar to the loss of *Cdkn1a* mRNA shown in Figure 3B at that time point. In sum, (in spite of a 4–6 week variability between animals of the same genotype), we found that p53 was transiently activated, peaking at around 4 months of age just before overt focal lesions are forming.

Since the above findings strongly suggested that the resulting neoplastic glands harbored mutant, inactive p53, we turned to sequencing the above prostate samples for *Trp53*-mutations at the level of the cDNA transcripts, which were abundant based on our Western results. As summarized in Figure 3D, we successfully isolated mutant forms of p53 (that were conserved in human and confirmed to be functionally inactivating, see Experimental Procedures) from 3 out of 5 *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> prostates analyzed (Figures 3C–D, see asterisks for Western and sequencing correlations). This was neither seen in the WT, or *Pten*<sup>+/-</sup> control prostates nor in the primary *Phlpp1*<sup>-/-</sup> MEFs (see Experimental Procedures).

Collectively, these data suggested that increased p53 activity could be observed around 4 months and was then lost at the 6 month and 8 month time points. They were also consistent with the notion that compound mutant prostates were under pressure to mutate p53.



Paradoxically, these findings suggested that, at 4 months, p53 activation (as revealed by transcription profiling) and inactivating mutation could occur in the same tissue and might give rise to tissue heterogeneity. Since this notion was consistent with the focal nature of tumorigenesis that we had already observed, we next explored the histological features of this process in more detail.

### p53 inactivation drives compound mutant escape from senescence

Based on the above findings we sought to visualize the molecular events in early *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> prostate at the microscopic level. We therefore tested the 4 month old compound mutant prostate that scored positive for p53 activation (Figure 3C and S3B, 4 months) and also harbored a p53 mutation (Figure 3D, 4months) for features of cellular senescence. Senescence associated  $\beta$ -galactosidase (SABG) staining revealed the presence of distinct positive blue areas in neoplastic glands, absent from the normal surrounding and from WT glands, and intriguingly also absent from the dysplastic core of the gland (Figure 4A). To confirm that this differential staining was due to molecular differences we tested pAkt activation by immunofluorescence and found an inverse staining pattern for pAkt (Ser<sup>473</sup>) activation in an adjacent section of the same gland (Figure 4B, area 1 vs. 2). Moreover the SABG positive peripheral area 1 showed few Ki-67 positive cells compared to the pAkt positive luminal area 2, consistent with cellular senescence (Figure 4B).

Thus, our data suggested that tumorigenesis in the *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> model requires the inactivation of p53 to escape from senescence (through spontaneous or pre-existing alterations). We found that *Phlpp1*<sup>-/-</sup> and *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> primary MEFs arrested in a growth assay when compared to WT MEFs (see Figure 4C). Indeed, we found increased p53 in these cells, correlating to pathway activation (see Figure 7A). Upon infection of these single and double mutant MEFs with a virus-based anti-p53 short hairpin (sh-p53 with Gfp marker) and Gfp-based tracking of the infected population we found that these cells underwent clonal expansion (see Figure 4D and Figure S3E) after 12 days post infection (without antibiotic selection, see Experimental Procedures) and we confirmed these results after deriving the stable anti-p53 hairpin expressing MEFs (Figure 4E). Of these, only (*Pten*/) *Phlpp1*-mutant cells could form colonies in agar (Figure S3G). We confirmed Akt-dependence of these cells using an AKT-inhibitory drug resulting in growth suppression, decreased cell viability and increased apoptosis (Figures S3H-I).

These data demonstrated that loss of p53 in a (*Pten*/) *Phlpp1*-mutant setting could switch cells from arrest into proliferation. Note that consistent with the previous reports on senescence after *Pten*-loss (Alimonti et al., 2010; Chen et al., 2005), we found no phospho-Ser<sup>15</sup> phosphorylation in the increased p53 of *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> prostate (Figure S3F) nor changes in phosphorylation on a panel of other p53 modification sites (see Experimental Procedures) in *Phlpp1* knockdown cells (not shown).

To summarize, our findings revealed that loss of *Phlpp1* in the context of partial *Pten*-loss causes p53 activation and cellular senescence in the prostate and in MEFs. While this fail-safe response can delay disease progression, we did observe that it is invariably overcome in the prostates of our mice. Our data thus suggested a general conceptual paradigm of triggering and breaking senescence as a condition for *Pten/Phlpp1*-mutant prostate tumorigenesis. However, in contrast to the natural human disease, every prostate cell in our engineered model suffers *Pten* and *Phlpp1*-loss, thus increasing the likelihood of spontaneous escape from arrest through either pre-existing or spontaneous p53-mutations. To test if and at what stage breaking of the p53 senescence response is important in the human disease, we validated this genetic progression scheme in a comprehensive human prostate cancer database.

### ***PHLPP1* is a tumor suppressor in human prostate**

To validate our findings in human prostate cancer, we studied a data set of 218 tumor samples (181 primary and 37 metastatic CaP specimens) from patients with clinical and pathologic annotation (Taylor et al., 2010). Of these, 128 samples were also profiled with gene expression arrays (see Experimental Procedures Section). We found that *PHLPP1* (18q21) was indeed lost at the genomic level in 29 cases (Figure 5A, top). As shown (Figure S4), 22 of 29 samples exhibited broad heterozygous loss of *PHLPP1* that often included the recently validated prostate cancer gene *SMAD4* (Ding et al., 2011). For comparison, 38 and 37 samples had either broad heterozygous or focal homozygous deletions involving *PTEN* or *TP53*, respectively. In addition, *PHLPP2* (on chromosome 16), the paralog of *PHLPP1*, was found in a region of frequent broad heterozygous loss (Figure S4). Moreover, these genes were often lost in the samples from metastatic sites (see Figure 5A, bottom).

We then tested for more specific *PHLPP1* alteration, first at the transcript level. As shown in Figure 5B (top), we found that genomic loss was significantly associated with reduced *PHLPP1* expression levels using statistical variance testing (p-value <0.001, see Experimental Procedures). We also identified eight human tumors in which *PHLPP1* was apparently diploid, but harbored reduced transcript expression levels (more than 2 standard deviations below the mean expression of 29 normal adjacent prostate samples). Similarly, we found statistically significant association between *PTEN* expression levels and its copy number (Figure S5A). To further explore the extent of *PHLPP1*-specific alteration in CaP, we analyzed tumor tissue microarrays (TMAs) for *PTEN* and *PHLPP1* proteins in the patients. As shown in Figure 5B (bottom), our analysis revealed that low or absent levels of *PTEN* or *PHLPP1* were 3–5 times more frequent than alteration at either DNA or RNA level. We also found some overlap between *PTEN* and *PHLPP1* protein loss (p=0.017). By integrating the TMA data with genomic and expression analysis on 79 samples we could demonstrate that the vast majority of *PTEN* and *PHLPP1* protein loss happens in cases with normal DNA and/or expression of the genes (Figure 5C).

Thus, both *PTEN* and *PHLPP1* are frequently and specifically targeted at the translational or post-translational level. Note that candidate exon re-sequencing of 80 tumors from this set identified few gene mutations (e.g. only two p53 mutant samples (Taylor et al., 2010)). We therefore chose not to re-sequence the full data set (no *PHLPP1* mutations were found in 9 samples). Our analysis confirmed that *PHLPP1* is frequently deleted in primary and advanced disease and also altered at the RNA- and, in particular, at the protein-level.

### **Co-deletion of *PHLPP1* and *PTEN* is strongly associated with metastatic disease**

Through mouse modeling we have discovered a relationship between triggering of a p53-fail-safe response by combined loss of *Pten* and *Phlpp1* on the one hand, and breaking it through loss of p53-function on the other. If, as previously suspected (Chen et al., 2005), senescence arrest after complete *PTEN/PHLPP1*-loss would suppress the early, still benign stages of disease, then the escaping prostate cancers would frequently present with triple alteration of *PTEN*, *PHLPP1* and *TP53*. Thus, we analyzed the human data set for co-alteration of these loci.

As shown (Figure 6A), primary samples showed no significant association between loss of *PHLPP1* and *PTEN*– this occurred in only one of the 181 samples, which had no deletion of *TP53*. In contrast, we found statistically significant co-deletion of *PTEN* and *PHLPP1* in metastatic samples. When testing for concomitant *PTEN*, *PHLPP1*, and *TP53* copy number alteration, we found statistically significant association (p-value < 2.6e–6, see also Figure 6A, legend) and frequent broad 16q co-deletion events which harbor the *PHLPP2* locus. Because the metastatic lesions harbor a greater number of alterations than the primary

samples, we performed two independent statistical analyses. First, we determined the genome-wide deletions, which are associated with *PTEN*-loss in metastatic samples as a function of the association's p-value. At  $p \leq 0.01$  (Figure 6C, left plot) we find that *PHLPP1* is in one of only 17 deletions containing 69 genes that are co-deleted with *PTEN* ( $p=0.008$ ). At higher p-value ( $\leq 0.05$ ) neighboring genes in the *PHLPP1* locus also became statistically significant, consistent with the recent discovery of *Pten/Smad4* cooperation in mouse (Ding et al., 2011). We indeed observed activation of Tgf-beta signaling in the *Phlpp1*-deficient mouse prostate (Figure S3D) and the human data showed significant association with further indicated events that were recently validated to strongly cooperate with loss of *Pten* in mouse (Carver et al., 2009a; Chen et al., 2005; King et al., 2009). Also, combined *PTEN-PHLPP1* loss correlates significantly with loss of *TP53* (Figure S5D).

Next, we performed an unbiased determination of significant co-deletions in metastases. To this end, we carried out a False Discovery Rate analysis by first performing a Monte Carlo permutation test of the significance of each possible co-deleted pair of genes in the metastatic genomes (total of >3000 genes giving 5 Mio pairs). The result is the histogram of p-values depicted in Figure S5C. As shown, the vast majority of these pairs are statistically consistent with absence of correlation: their p-values form a constant plateau in the graph. In contrast, there is a number of true positives, i.e. gene pairs that are significantly correlated, statistically. These are exhibited by the overrepresentation of low p-values to the left side of the graph (see also Experimental Procedures). This small subset of significantly correlated genes contains all the pertinent gene pairs formed by loss of *PTEN*, *PHLPP1*, *PHLPP2* and *TP53*. Considering that these are physically independent genes, they are statistically likely to be biologically linked.

To summarize, our two additional analyses confirm that the metastatic samples show a statistically significant enrichment of co-deletion of these genes, while in contrast, the primary samples do not. When we analyzed the heat-map of inactivation of these genes among only metastatic samples (shown in Figure 6B), we indeed observed that co-deletion of *PTEN*, *PHLPP1*, *PHLPP2* and *TP53* clustered together. These data are consistent with a prostate cancer progression model, where loss of p53 is a prerequisite for the combined loss of *PTEN* and the *PHLPP* genes, which is found in metastasis.

Taken together, our analysis suggests that (i) *PHLPP1* is a tumor suppressor in human prostate cancer, that (ii) strong activation of AKT signaling through loss of *PTEN* and *PHLPP1* is associated with the loss of *TP53*, and that (iii) the co-incidence of these three deletion events is frequent in metastatic samples but absent from primary tumors. These data are thus consistent with the notion that the p53-response acts as a barrier to prostate cancer progression, and not initiation. However, we note that our analysis does not allow us to conclude the order in which these three human deletion events occur.

To test if the latter finding could be of clinical value, we analyzed if combined alteration of *PTEN* and *PHLPP1* at RNA or protein level could predict disease recurrence after prostatectomy. *PTEN/PHLPP1* protein levels did not correlate with disease recurrence (not shown). Plotting the combined transcript levels of *PTEN* and *PHLPP1* in prostatectomies (Figure 6D), we did observe a significant difference between the time to biochemical relapse in *PTEN/PHLPP1* low mRNA samples and those with at least one normal transcript level ( $p=4E-5$ ). This outcome analysis was similar to using the histopathology based Gleason score as predictor in this data set (Figure 6D). These results suggest that combining pathology based information with the *PTEN/PHLPP1* transcript signature could identify patients that would benefit from PI 3-Kinase pathway therapy. Note that only 3 (of 37) samples with low *PTEN/PHLPP1* transcripts had Gleason scores of 7. Thus, we could not test if the transcript levels could significantly stratify this important patient group. When



performing this analysis with other pairs that are associated with low PTEN expression including cancer genes near the *PHLPP1* locus (Figure S5B, bottom) only the *PTEN/SMAD4* combination stood out with significant predictive power (Figure S5E) consistent with recent findings (Ding et al., 2011).

### Phlpp2 and p53 show a concerted response to *Pten/Phlpp1* status

Finally, we asked why late stage samples consistently showed loss of the *PHLPP2* gene (Figure 6B, bottom) when *PTEN/PHLPP1* deletion could already drive the pathway to prostate cancer, especially after loss of p53. To this end, we studied Phlpp2 regulation in the genetically defined setting of primary WT, *Phlpp1*<sup>-/-</sup> and *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> double mutant MEFs. As shown in Figure 7A, both *Phlpp1* mutant settings resulted in increased Phlpp2 as well as increased p53 levels. To test if this response was elicited by AKT activation, we used NIH-3T3 cells stably transfected with constitutively active AKT (via myristoylation, myr-AKT, Figure 7B). This experiment confirmed AKT dependent increase in Phlpp2 and p53 levels. Importantly, a myr-AKT plasmid that was targeted exclusively to the cytoplasm (myr-AKT-NES, see Figure S6A for localization) was also able to induce the two proteins consistent with a Phlpp2 and p53 response triggered by cytoplasmic AKT. To confirm that Phlpp2 and p53 levels are coupled to Pten and Phlpp1 levels we used RNAi in this cell line. As shown (Figures 7C and S6B), combined *Pten/Phlpp1* knockdown resulted in increased Phlpp2 and p53 levels, confirming a putative negative feedback mechanism. Next, we tested this response in a controlled setting with a human PTEN knockout cell line, the HCT116 *PTEN*<sup>+/+</sup> and *PTEN*<sup>-/-</sup> system (Kim et al., 2006). Figure S6C shows that the *PTEN*-deficient cells display activation of pAKT and p53, as published (Kim et al., 2006). At the same time these *PTEN* null cells also exhibited strong PHLPP2 activation, consistent with our findings in primary and immortalized mouse cells.

To better understand these findings mechanistically, we tested if the Phlpp2 protein response was caused by increased transcript levels or protein stability in the NIH-3T3 *Pten/Phlpp1* knockdown cells. However (see Figure S6D–E), we found neither increased RNA levels and slightly decreased, not increased Phlpp2 stability after *Pten/Phlpp1* knockdown. This transcript-independent principle was confirmed in the compound mutant prostate, and we confirmed that reversal of this surge by Phlpp2 knockdown results in Akt activation in compound mutant MEFs (Figure S6F–G). Since we found inactivation of the Tsc2-axis after *Phlpp1*-loss (Figure S6H), we tested if the response was mediated by translation downstream of mTOR, as previously shown for p53 upon loss of *Pten* (Alimonti et al., 2010). Intriguingly, using the *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> primary MEFs (Figure 7D), addition of rapamycin abrogated the Phlpp2 activation that persisted in the DMSO control treatment. Similarly (see Figure 7E), rapamycin also blunted the Phlpp2/p53 feedback in the NIH-3T3 cells, which were stably transfected with myrAKT- or the anti-*Pten/Phlpp1* RNAi-plasmids (Figure 7E–F). Finally, we confirmed that genetic activation of mTORc1 by *Tsc1*<sup>-/-</sup> ablation also leads to a strong Phlpp2 surge without increasing its transcript (Figure S6I).

Taken together, our data show that in the genetically defined context of *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> primary MEFs, Phlpp2 positively responds to pathway activation in an mTORc1-dependent manner, similar to p53. These findings suggest that the high co-deletion rate of the *PHLPP1/2* and *TP53* genes with *PTEN* in advanced cancer is required to break this feedback in late stage disease. Furthermore, our results suggest that clinically relevant pathway inhibitory drugs that target mTORC1 could negatively affect the levels of PHLPP2 and p53 in patients.

## DISCUSSION

Cancer researchers are facing a deluge of genome data. Turning this powerful information into our advantage ultimately depends on highly reliable systems for experimental validation. Our study shows how data from large scale genomics can be put into a meaningful biological context and transformed into actionable information by comparison with results from hypothesis driven research in genetically engineered mice.

First, we have identified in *PHLPP1*, a ‘druggable’ suppressor of prostate cancer progression since its antagonist, mTORC2 can be pharmacologically inhibited. Most importantly, genetic mTORC2-inactivation has no adverse effects on adult prostate tissue (Guertin and Sabatini, 2009). The deletion involving *PHLPP1* (18q21) contains still other suspected and confirmed tumor suppressors. The TGF-beta effectors SMAD2, SMAD4, SMAD7, as well as the *DCC* gene, are co-deleted in the majority of cases. The cooperation of *Smad4* with complete *Pten*-loss in prostate cancer has recently been shown in knockout mice (Ding et al., 2011) and similarly, we find Smad-activation in response to *Phlpp1*-loss in prostate. The co-deletion of *SMAD4* and *PHLPP1* could thus conceivably exacerbate the consequences of *PTEN*-loss in human prostate.

Second, our study reveals a progression principle of PTEN-pathway driven aggressive prostate cancer. After its initial discovery (Chen et al., 2005), the senescence response in prostate was primarily thought to protect early hyperplastic precursor lesions from becoming clinically relevant cancer (reviewed in (Narita and Lowe, 2005)). In contrast, our genomic analysis reveals that strong activation of the pathway coincides with p53-deletion in metastasis, not cancer. Therefore we propose that primary prostate lesions *must and do* develop in *PTEN* haploinsufficiency (75% show reduction in protein) in order to fly below the radar of the p53 activation system unless a p53 alteration has already occurred.

Third, we find that low *PTEN/PHLPP1* transcription correlates with biochemical relapse in patients after prostate surgery. If confirmed in expanded studies, this finding could yield important molecular information that might be used to stratify patients for PI 3-Kinase inhibitor trials. Importantly, recent results (Carver et al., 2011; Mulholland et al., 2011) have revealed that blockade of AR- or PI 3-Kinase signaling is mutually reinforcing, demonstrating the need for combined therapeutic pathway inactivation. Intriguingly, this research has shown that AR-mediated AKT-inhibition is carried out by *PHLPP1* activation since *PHLPP1* is degraded by AR blockade, a mainstay of advanced prostate cancer therapy. These results reinforce the crucial role of *PHLPP1* status in prostate cancer progression.

Finally, we identify the *PHLPP2* protein as part of a cell autonomous fail-safe mechanism, which in concert with p53 responds to excessive pathway signaling in prostate. The activation of these responses cannot prevent tumorigenesis in our animal system, yet they critically shape the disease time course in a model where, unlike in human, every prostate cell is engineered to suffer *Pten/Phlpp1*-loss. The *PHLPP2*-mediated negative pathway feedback represents another potential mechanism by which mTORC1 activation inhibits AKT activity. Since the pharmacological inhibition of mTORC1 is able to derail this response, our data argue for checking this *PHLPP2* activation in patients before they receive mTORC1-targeting pathway therapy.

Taken together, our results identify the critical role of the *PHLPP* proteins in prostate cancer and suggest that defining their status in relation to *PTEN* and p53 is important for understanding and combatting the disease.

## Experimental Procedures

### Mice

Generation of *Phlpp1* knockout mice was recently described (Masubuchi S *et al. Proc Natl Acad Sci USA. 2010 Jan 26;107(4):1642-7*). *Phlpp1* null mice (129 Sv/C57BL6) were crossed with wild-type mice (129 Sv/C57BL6, from our *Pten*<sup>+/-</sup> cohort) for two generations. Offspring were intercrossed for 6 generations to obtain the study cohort of over 400 animals. For genotyping, PCR primers 5'-TGGGAAGAACCTAGCTTGGAGG-3' and 5'-TTCCATTTGTCACGTCCTGCAC-3' and 5'-ACTCTACCAGCCCAAGGCCCGG-3' were used for *Pten*. Primers 5'-TAGGAGAGACTAGTGACATC-3' and 5'-TGAGCTTATACGCTGTGATGC-3' and 5'-AGCCGATTGTCTGTTGTGC-3' were used for *Phlpp1*. Overall and disease-free survival curves were calculated by the Kaplan-Meier method and Log Rank (Mantel-Cox) testing with Prism 5.0 software for Apple Macintosh OS X. Cohort sizes were 411 mice for overall survival (WT (98), *Phlpp1*<sup>+/-</sup> (97), *Phlpp1*<sup>-/-</sup> (49), *Pten*<sup>+/-</sup> (45), *Pten*<sup>+/-</sup>;*Phlpp1*<sup>+/-</sup> (81), *Pten*<sup>+/-</sup>;*Phlpp1*<sup>-/-</sup> (41)), and 37 animals for prostate cancer free survival (WT (6), *Pten*<sup>+/-</sup> (5), *Phlpp1*<sup>-/-</sup> (9), *Pten*<sup>+/-</sup>;*Phlpp1*<sup>+/-</sup> (6), *Pten*<sup>+/-</sup>;*Phlpp1*<sup>-/-</sup> (11)). All work with animals was performed along the CSHL IACUC approved protocol # 11-08-3 "Tumor suppressor mutation in mouse models for cancer (11-08-3), Trotman, PI).

### Western Blotting

Prostates from dissected animals of all genotypes were homogenized and protein was extracted simultaneously with DNA and RNA using the AllPrep DNA/RNA/Protein kit (Qiagen) per manufacturer's instructions. Cells were lysed in 50mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, 1 mM sodium ortho-vanadate (Na<sub>3</sub>VO<sub>4</sub>), 10 mM NaF, protease inhibitor cocktail (Roche) and cleared by centrifugation; concentrations were determined by Bio-Rad Protein Assay (Bio-Rad Laboratories). Resulting samples were taken into an SDS sample loading buffer followed by brief sonication and centrifugation, then the supernatant was collected for western blotting. Prostate and MEFs were from at least two sets of mice of all genotypes and samples were analyzed three times or more for confirmation.

### Cluster Analysis

Gene set or pathway analysis was done by using GAGE (Luo W *et al. BMC Bioinformatics* 2009, 10:161.), generally applicable gene set enrichment. The most differentially regulated KEGG pathways and GO groups were selected with FDR q-value < 0.1. In significant KEGG pathways or GO groups, genes with above noise-level expression changes are taken to be substantially perturbed. These data were then row/gene-wise normalized and visualized using heat-maps.

### Plasmids and stable lines

pCDNA3-Myr-HA-AKT plasmid was obtained from Addgene (originally generated by William Sellers, Addgene plasmid 9008). pCDNA3-Myr-HA-AKT-NES was constructed by cloning synthetic oligos corresponding to the nuclear export signal (NES) of the PKI protein to the 3-prime end of Myr-HA-AKT. Plasmids were transfected into NIH3T3 cells using Lipofectamine 2000 (Invitrogen), and selected with 800 µg/ml neomycin 48 hours post-transfection to generate stable lines.

### Human prostate cancer data

For the analysis of human prostate tumors, 218 frozen prostate cancer specimens and 149 matched normal tissue samples were procured from patients treated by radical prostatectomy

at Memorial Sloan-Kettering Cancer Center. DNA from 194 tumor specimens were labeled and hybridized along with either their matched normal tissue or a pool of reference normal to Agilent 244K array comparative genomic hybridization arrays (aCGH) using the manufacturer's protocol. Raw copy number profiles were normalized, segmented with Circular Binary Segmentation (Venkatraman and Olshen, *Bioinformatics*. 2007 Mar 15;23(6):657-63.) and analyzed with RAE as previously described in Taylor BS et al, *PLoS One*. 2008 Sep 11;3(9). Expression levels were determined for 128 of these tumors and 29 normal prostate tissues using Affymetrix Human Exon 1.0 ST arrays and tested for their association with copy number status by Anova testing as published (Taylor et al., 2010). For clinical evaluation, data from this work was previously analyzed by the Memorial Sloan Kettering Cancer Center (MSKCC) Prostate Cancer Oncogenome Group. Clinical and pathologic data from this patient cohort is maintained in a prospective fashion on the MSKCC prostate cancer clinical database and the published data on 181 primary and 37 metastatic tumors (Taylor et al., 2010) have been visualized using the Nexus Copy Number software v 5.1 (Biodiscovery, Inc.). All analyses for this publication were performed on de-identified patient data and material and thus qualified for exemption from human subjects statements under 45 CFR 46.101 (b) (4).

#### Highlights

- *PHLPP1* is a prostate tumor suppressor that cooperates with *PTEN*
- *Phlpp1/Pten* co-deletion requires p53 inactivation for senescence bypass
- Co-deletion is associated with metastatic disease
- Co-deletion triggers rapamycin-sensitive p53 and Phlpp2 activation

#### Significance

Excessive AKT activity triggers p53-dependent growth arrest in mouse prostate. However, it has remained ill-defined if and at what stage this response acts in human prostate cancer. We now show that this surveillance mechanism forms a common barrier against prostate cancer progression. It antagonizes the co-deletion of the AKT suppressors *PTEN* and *PHLPP1*, whose deletions are mutually exclusive in primary cancers. Since rapamycin strongly inhibits the feedback activation of p53 and Phlpp2, our data call for checking the status of this fail-safe response before patients receive mTorc1-targeting therapy. Collectively, our findings identify the PHLPP proteins as key players in prostate cancer and reveal the tightly orchestrated nature of tumor suppressor activity in this disease.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank S. Lowe, S. Powers, M. Zhang, K. Maimer, J. Hicks, M. Spector, J. Zuber, and W. Xue for discussion, help with analyses, and reagents, L. Bianco, A. Nourjanova, K. Manova, and A. Barlas for help with histology procedures and analysis, R. McCombie and S. Muller for help with sequencing, M. Hammell, W. Luo, and C. Johns for discussion and help with RNA expression array production and evaluation, and J. Simon and M. Taylor for discussion of animal procedures. This work was supported by grants to L.C.T. from the Department of the Army (W81XWH-09-1-0557), the Starr Foundation (I3-A154), the V Foundation, the V Kann Rasmussen Foundation (VKRF), and the NIH (1R01CA137050-01A2), as well as by the MSKCC Prostate SPORE and NIH grant GM-43154 to A.C.N. L.C.T. is a Rita Allen Foundation Scholar and would like to dedicate this work to the memory of William L. Gerald.

## Abbreviations

Gene/Protein species nomenclature convention was used. Example:

<b><i>PTEN</i></b>	human gene
<b>PTEN</b>	human protein
<b><i>Pten</i></b>	murine gene
<b>Pten</b>	murine protein
<b>H&amp;E</b>	Haematoxylin-Eosin
<b>pAkt</b>	phospho-Ser <sup>473</sup> -Akt, unless otherwise noted
<b>PHLPP</b>	PH domain Leucine-rich repeat Protein Phosphatase. Note that the <i>PHLPP1</i> gene has been renamed from <i>PHLPP</i> , as has the closely related paralog <i>PHLPP2</i> (formerly <i>PHLPL</i> ) gene
<b>PI</b>	Propidium Iodide
<b>PIN</b>	Prostatic Intraepithelial Neoplasia
<b>PIP<sub>3</sub></b>	Phosphatidylinositol (3,4,5)- trisphosphate
<b>PKC</b>	Protein Kinase C
<b>PM</b>	Plasma Membrane
<b><i>Trp53</i></b>	Transformation Related Protein 53 gene, p53-gene
<b>s.d.</b>	standard deviation


## References

- ACS. The American Cancer Society; 2007–2009. Combined Cancer Statistics 2007 to 2009.
- Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. *Sci Signal*. 2009; 2 pe27.
- Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. *J Clin Invest*. 2010; 120:681–693. [PubMed: 20197621]
- Brogna J, Sieracki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. *Mol Cell*. 2007; 25:917–931. [PubMed: 17386267]
- Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandralapaty S, Arora VK, Le C, Koutcher J, Scher H, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. *Cancer Cell*. 2011; 19:575–586. [PubMed: 21575859]
- Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP. ETS rearrangements and prostate cancer initiation. *Nature*. 2009a; 457:E1. discussion E2–3. [PubMed: 19212347]
- Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. *Nat Genet*. 2009b; 41:619–624. [PubMed: 19396168]
- Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. *Science*. 2003; 301:215–218. [PubMed: 12855809]
- Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature*. 2005; 436:725–730. [PubMed: 16079851]



- Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. *Genes Dev.* 2011; 25:534–555. [PubMed: 21406553]
- Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. *Nat Rev Cancer.* 2010; 10:51–57. [PubMed: 20029423]
- Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. *Nat Genet.* 2001; 27:222–224. [PubMed: 11175795]
- Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten<sup>+/-</sup> mice. *Science.* 1999; 285:2122–2125. [PubMed: 10497129]
- Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. *Nature.* 2011; 470:269–273. [PubMed: 21289624]
- Frese KK, Tuveson DA. Maximizing mouse cancer models. *Nat Rev Cancer.* 2007; 7:645–658. [PubMed: 17687385]
- Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. *J Biol Chem.* 2008; 283:6300–6311. [PubMed: 18162466]
- Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. *Mol Cell.* 2005; 18:13–24. [PubMed: 15808505]
- Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. *Sci Signal.* 2009; 2 pe24.
- Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. *Cancer Cell.* 2009; 15:148–159. [PubMed: 19185849]
- Kim JS, Lee C, Bonifant CL, Ransom H, Waldman T. Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA. *Mol Cell Biol.* 2006
- King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, Leung DH, Taylor BS, Sander C, Cardiff RD, Couto SS, et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. *Nat Genet.* 2009; 41:524–526. [PubMed: 19396167]
- Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. *Cancer Res.* 2007; 67:8504–8510. [PubMed: 17875689]
- Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nat Med.* 2009; 15:559–565. [PubMed: 19363497]
- Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem.* 1998; 273:13375–13378. [PubMed: 9593664]
- Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. *Oncogene.* 2005; 24:7465–7474. [PubMed: 16288293]
- Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. *Proc Natl Acad Sci U S A.* 2003; 100:7841–7846. [PubMed: 12799464]
- Masubuchi S, Gao T, O'Neill A, Eckel-Mahan K, Newton AC, Sassone-Corsi P. Protein phosphatase PHLPP1 controls the light-induced resetting of the circadian clock. *Proceedings of the National Academy of Sciences of the United States of America.* 2010; 107:1642–1647. [PubMed: 20080691]
- Mullholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H. Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth. *Cancer Cell.* 2011; 19:792–804. [PubMed: 21620777]
- Narita M, Lowe SW. Senescence comes of age. *Nat Med.* 2005; 11:920–922. [PubMed: 16145569]
- Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretto G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. *Proc Natl Acad Sci U S A.* 1999; 96:1563–1568. [PubMed: 9990064]
- Saramaki O, Visakorpi T. Chromosomal aberrations in prostate cancer. *Front Biosci.* 2007; 12:3287–3301. [PubMed: 17485299]

- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science*. 2005; 307:1098–1101. [PubMed: 15718470]
- Schreiber SL, Shamji AF, Clemons PA, Hon C, Koehler AN, Munoz B, Palmer M, Stern AM, Wagner BK, Powers S, et al. Towards patient-based cancer therapeutics. *Nat Biotechnol*. 2010; 28:904–906. [PubMed: 20829823]
- Shariat SF, Scardino PT, Lilja H. Screening for prostate cancer: an update. *Can J Urol*. 2008; 15:4363–4374. [PubMed: 19046489]
- Shimizu K, Mackenzie SM, Storm DR. SCOP/PHLPP and its functional role in the brain. *Mol Biosyst*. 2010; 6:38–43. [PubMed: 20024065]
- Shimizu K, Okada M, Nagai K, Fukada Y. Suprachiasmatic nucleus circadian oscillatory protein, a novel binding partner of K-Ras in the membrane rafts, negatively regulates MAPK pathway. *J Biol Chem*. 2003; 278:14920–14925. [PubMed: 12594205]
- Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. *Cancer Cell*. 2010; 18:11–22. [PubMed: 20579941]
- Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. *Nature*. 2006; 441:523–527. [PubMed: 16680151]
- Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, et al. Pten dose dictates cancer progression in the prostate. *PLoS Biol*. 2003; 1:E59. [PubMed: 14691534]
- Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. *Curr Opin Genet Dev*. 2010; 20:87–90. [PubMed: 20006486]




**Figure 1. *Phlpp1* is a tumor suppressor and dictates carcinogenesis in *Pten* heterozygous mice**  
**(A)** Kaplan-Meier plot for overall survival. Number of mice (**n**) and statistical significance (**p**) is given for comparison between *Pten*<sup>+/-</sup> and *Pten*<sup>+/-</sup>;*Phlpp1*<sup>-/-</sup> mice and between WT and *Phlpp1*<sup>-/-</sup> mice. Numbers in cohort arms are: WT (98), *Phlpp1*<sup>+/-</sup> (97), *Phlpp1*<sup>-/-</sup> (49), *Pten*<sup>+/-</sup> (45), *Pten*<sup>+/-</sup>;*Phlpp1*<sup>+/-</sup> (81), and *Pten*<sup>+/-</sup>;*Phlpp1*<sup>-/-</sup> (41) for a total of 411 animals.

**(B)** Kaplan-Meier plot for invasive-free survival showing complete penetrance of prostate cancer in *Pten*<sup>+/-</sup>;*Phlpp1*<sup>-/-</sup> animals. p-value for *Pten*<sup>+/-</sup>;*Phlpp1*<sup>-/-</sup> comparison with WT animals is shown. Numbers in cohort arms are: WT (6), *Pten*<sup>+/-</sup> (5), *Phlpp1*<sup>-/-</sup> (9), *Pten*<sup>+/-</sup>;*Phlpp1*<sup>+/-</sup> (6), *Pten*<sup>+/-</sup>;*Phlpp1*<sup>-/-</sup> (11) for a total of 37 animals (ns., not significant).

**(C)** Microscopic analysis of 8 month prostate lesions reveals high grade PIN in *Phlpp1*<sup>-/-</sup> and adenocarcinoma in *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> prostates, as indicated. Insert shows high magnification. Scale bar, 100μm. (See also Figures S1A, B).

**(D)** Analysis of cell proliferation in prostate at 8 months using Ki-67 immunohistochemistry (left panels, scale bar, 50μm) reveals increased proliferation in compound mutant. Progression of disease over time as shown by average Ki-67 positive cells per 100 in neoplastic foci (graph, see also Experimental Procedures). p-values are < 0.0001 and < 0.004 for comparison of compound mutant prostates (*Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup>) with *Phlpp1*<sup>-/-</sup> or *Pten*<sup>+/-</sup>, respectively at 8 months and p < 0.0006 and < 0.003, respectively at 12 months. Error bars are s.d. See also Figures S1C, D.





**Figure 2. *Phlpp1*-loss in prostate triggers Akt Ser<sup>473</sup> activation and localization to plasma membrane**

(A) Western blotting of Akt activation in 8 month old prostates and quantification of pAkt Thr<sup>308</sup>: Akt and pAkt Ser<sup>473</sup>: Akt ratios reveals strong phosphorylation on the hydrophobic Ser<sup>473</sup> motif. See also Figures S2A–D.

(B) Western blotting and quantification of Erk and Mek kinase activation (Asterisks denote actin leftover staining on blot) reveals no activation of this signaling axis in *Pten*/*Phlpp1*-mutant prostate.




**(C)** time course of signal activation by IHC staining for pAkt Ser<sup>473</sup> demonstrates activation and strong membrane localization in compound mutant genotypes after 4 months of age. Scale bar, 100  $\mu$ m.


**(D)** PHLPP1-IHC staining in human prostate cancer sample reveals membrane localization in epithelium. Scale bar, 50  $\mu$ m.

**(E)** Examples of differential PHLPP1 levels in human prostate cancers as detected by PHLPP1-IHC staining of the Tumor Tissue Microarray. Scale bar, 50  $\mu$ m.


A



B



C



D

Genotype	Age (mo.)	Mutation (Mm)	Corresponding mutation (Hs)
<i>Pten</i> <sup>+/-</sup> ; <i>Phlpp1</i> <sup>-/-</sup>	* 4	S124P	S127P
	** 6	S124P	S127P
	11	I252T V144A	I255T V147A
<i>Phlpp1</i> <sup>-/-</sup>	6	F267L	F270L
<i>Phlpp1</i> <sup>-/-</sup> MEF		-	-
wt mice	4; 8	-	-

### Figure 3. p53 activation and mutation occurs in *Pten/Phlpp1*-mutants


(A) Western blotting and quantification of p53 shows increase in p53 levels in the *Phlpp1* mutant prostates at 8 months of age. See also Figure S3A.

(B) RT-qPCR of *p21*<sup>waf1</sup> transcripts extracted from the same lysates as shown in (A) reveals lack of p21 activation in spite of p53 protein increase in the *Phlpp1* mutant tissues. Bars represent different primer pairs. Error bars are s.d. of triplicates.


(C) Western blotting of p53 and p21 induction in prostates from indicated ages and genotypes confirms loss of p53 activity at 6 months. See also Figures S3B and S6F.

(D) Summary of p53 inactivating mutations identified in above mouse prostates of indicated genotypes and ages. Asterisks denote that analyses were derived from identical samples (see also Experimental Procedures).


A




B




C



D



E




#### Figure 4. p53 inactivation and escape from senescence

(A) H&E (left) and corresponding adjacent section staining for senescence-associated beta-galactosidase (SABG, right) in 4 month old prostates of indicated genotypes. Note that the peripheral area 1 is SABG positive, and the central luminal area 2 is SABG negative, indicative of tissue heterogeneity. Red asterisks denote basal lamina. Scale bar, 200  $\mu$ m.

(B) Immunofluorescence on adjacent sections of *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> prostate gland from (A) reveals strong pAkt Ser<sup>473</sup> activation (top) and proliferation as measured by Ki-67 (bottom) in the SABG-negative luminal area 2. In contrast, the SABG-positive area 1 shows few Ki-67 positive cells, and weak pAkt. Red asterisks denote basal lamina. Scale bar, 100  $\mu$ m.

- (C)** Growth curve of WT, *Phlpp1*<sup>-/-</sup>, and *Pten*<sup>+/-</sup>;*Phlpp1*<sup>-/-</sup> MEFs reveals suppressed proliferation in compound mutant genotypes. Error bars are s.d. of triplicates.
- (D)** p53-knockdown bypasses growth suppression in the *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> and *Phlpp1*<sup>-/-</sup> mutant primary MEFs leading to clonal outgrowth of the sh-p53 positive cells (See also Figure S3E). Genotypes of primary MEFs are WT (blue), *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup> (brown), *Phlpp1*<sup>-/-</sup> (red). Hatched lines denote control shRNA-Luciferase infections (same color code).
- (E)** Growth curves of *Phlpp1*<sup>-/-</sup>; shp53 and *Pten*<sup>+/-</sup>; *Phlpp1*<sup>-/-</sup>; shp53, and shp53 MEFs confirm results from (D) after selection of stably transduced cells. Error bars are s.d. of triplicates.




**Figure 5. *PHLPP1* is a tumor suppressor of human prostate cancer**

(A) Upper panel: copy number loss of *PTEN*, *PHLPP1*, *TP53* and *PHLPP2* in the data set of 218 human prostate cancer samples (see Experimental Procedures). Lower panel: deletion frequency of above genes in the 181 primary tumors and 37 metastases. See also Figure S4.


(B) *PHLPP1* copy number alterations correlate with gene expression profiling (top). Boxes contain expression values of 50% of cases, bars show the remaining 50% except for rare outliers. A bold line indicates the median expression value. Z-scores are relative to expression in normal prostate. Bottom graph: overview of alteration frequencies in 79 samples that were triple-analyzed at copy number, RNA expression and protein level for *PTEN* and *PHLPP1*.

(C) Breakdown of alterations in samples with low *PTEN* (top) and *PHLPP1* (bottom) protein levels. Protein reduction (scored low or absent) in cancers is observed most frequently in spite of the presence of both gene copies and normal RNA levels.





**Figure 6. Co-deletion of *PHLPP1* and *PTEN* is restricted to the metastatic samples**  
**(A)** Co-deletion analysis of *PTEN*, *PHLPP1* and *TP53* in primary and metastatic samples shows frequent co-deletion in metastatic samples. The p-values for the significance of association between both *PTEN* and *PHLPP1* loss of any kind with primary (asterisk) or metastatic (double asterisk) samples are indicated. A triple asterisk denotes the p-value for the association of *PTEN*, *PHLPP1* and *TP53* triple-loss among all samples (no triple deletion occurred in primary samples). See also Figure S5A, B.  
**(B)** Heat map of copy number alteration in the 37 metastatic samples shows association of *PTEN*, *PHLPP1*, *PHLPP2* and *TP53* alterations. Color code for deletion and amplification is indicated. See also Figure S5C.  
**(C)** Circos plot of genome-wide co-deletion events in *PTEN*-mutant metastatic samples at  $p \leq 0.01$ . *PHLPP1* (with two next neighbors,  $p=0.008$ ) is in one of 17 *PTEN*-associated deletion regions that harbor a total of 69 genes. Right panel: at  $p \leq 0.05$  a greater number of deletions are associated with *PTEN*-loss. See also Figure S5D.  
**(D)** Kaplan-Meier outcome analysis for relapse after radical prostatectomy based on expression levels of *PTEN* and *PHLPP1* mRNA. The same analysis based on Gleason-scoring is shown for reference. Patients with Gleason score 6 (asterisks) and 7 (arrowheads) are shown. See also Figure S5E.



**Figure 7. Pten/Phlpp1 co-deletion triggers rapamycin-sensitive p53 and Phlpp2 activation**  
**(A)** A surge of steady state Phlpp2 and p53 levels is seen in the primary *Phlpp1<sup>-/-</sup>* and the *Pten<sup>+/-</sup>;Phlpp1<sup>-/-</sup>* mutant MEFs. See also Figure S6B, C, F.  
**(B)** Activated cytoplasmic AKT overexpression recapitulates the Phlpp2 and p53 activation from (A) in NIH-3T3 cells. See also Figure S6A.  
**(C)** The Phlpp2/p53 response is also found after shRNA-mediated *Phlpp1/Pten* knockdown in NIH-3T3 cells. See also Figure S6D, G.  
**(D)** The surge of Phlpp2/p53 in double mutant primary MEFs from (A) is blocked by rapamycin suggesting mTor dependent translation (see also Figure S6D, E).  
**(E)** Phlpp2/p53 activation driven by myrAKT overexpression in NIH-3T3 cells is blunted by rapamycin.  
**(F)** Phlpp2/p53 activation after *Pten/Phlpp1* knockdown in NIH-3T3 cells is reverted by rapamycin. See also Figures S6D, E, H, I)